The effect of GLP-1R agonists on eGFR decline and hard renal endpoints (ESRD or eGFR <15 mL/min/1.73 m2) still remains unknown, and should be explored in dedicated renal outcome studies with longer follow-up times in patients with T2DM and more advanced CKD at baseline. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.